Octodrine

Octodrine

Clinical data
Other names	DMHA; Ottodrina; Vaporpac; Amidrine; 2-Aminoisoheptane; 2-Amino-6-methylheptane; 1,5-Dimethylhexylamine; 6-Methyl-2-heptylamine; 6-Methyl-2-heptanamine[1]
Routes of administration	Oral, inhaled
ATC code	none
Legal status
Legal status	US: Unapproved "New Drug" (as defined by 21 U.S. Code § 321(p)(1)). Use in dietary supplements, food, or medicine is unlawful; otherwise uncontrolled.[2]
Identifiers
IUPAC name 6-methylheptan-2-amine
JSmol)	Interactive image
SMILES CC(C)CCCC(C)N
InChI InChI=1S/C8H19N/c1-7(2)5-4-6-8(3)9/h7-8H,4-6,9H2,1-3H3 Key:QNIVIMYXGGFTAK-UHFFFAOYSA-N
(verify)

Octodrine (also known as Vaporpac or DMHA) is a stimulant drug whose pharmacology was studied in a dozen animal studies from the 1940s through the 1970s. These studies found that octodrine can increase blood pressure and cardiac output in animals. The drug was previously approved for use by the FDA as an inhalant (i.e., Vaporpac and Tickle Tackle Inhaler) and in Germany as an oral agent as part of a multicomponent medication (i.e., Ambredin and Ordinal), but is no longer available.^[3]

DMHA has also been found as an adulterant in sports supplements and is sold online as a designer drug.^{[3] [4]}

Related designer drugs

• Methylhexanamine
• 1,3-Dimethylbutylamine (DMBA)

References